$599
Amgen, Terns, and 89bio Q2 ‘24 Earnings; NeuroBo Partners for QM Obesity Asset Formulation
A series of cardiometabolic-related news items have been observed from Amgen, NeuroBo Pharmaceuticals, Terns Pharmaceuticals, and 89bio. Below, FENIX provides highlights and insights for the respective news items.